A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Pralsetinib’s First Domestic Launch In China

CStone Pharmaceuticals (SEHK:2616) has announced the first domestically produced batch of pralsetinib capsules in China, starting nationwide distribution and leveraging National Reimbursement Drug List inclusion alongside significant year-on-year sales growth.

See our latest analysis for CStone Pharmaceuticals.

The latest product news comes after a strong run in CStone Pharmaceuticals’ stock, with the share price at HK$8.02 and a year-to-date share price return of 50.19%. The 1-year total shareholder return of 126.55% points to building momentum, despite a 17.15% share price pullback over the past month.

If you are comparing CStone’s progress with other healthcare names using AI, it is worth scanning the broader opportunity set with our focused screener for 127 healthcare AI stocks

With the stock up 50.19% year to date and trading below the HK$14.20 analyst target, investors now face a key question: Is CStone still undervalued, or is the market already pricing in future growth?

Preferred Price-to-Sales of 41.2x: Is It Justified?

CStone currently trades on a P/S ratio of 41.2x, which is high relative to both its peers and the wider Hong Kong biotechs industry, even after the recent share price pullback to HK$8.02.

The P/S ratio compares the company’s market value to its revenue, which is useful for loss making biopharmaceutical stocks where earnings are still negative. With HK$269.58 million of revenue and a market cap of about HK$12.82b, investors are clearly paying a sizeable premium for each dollar of current sales. This suggests the market is placing strong weight on future commercialisation of its oncology pipeline rather than present profitability.

That premium becomes even clearer when set against the benchmarks. CStone’s 41.2x P/S sits well above the Hong Kong biotechs industry average of 12.2x and also above the peer average of 37.8x. Compared with an estimated fair P/S ratio of 8.2x, the current multiple is several times higher. This is a level the market could move towards if expectations cool or revenue growth does not keep pace.

Explore the SWS fair ratio for CStone Pharmaceuticals

Result: Price-to-Sales of 41.2x (OVERVALUED)

However, the current 41.2x P/S sits far above sector levels, and ongoing net losses of CN¥437.003 million leave little room if sentiment cools.

Find out about the key risks to this CStone Pharmaceuticals narrative.

Another View Using Our DCF Model

While the 41.2x P/S points to an expensive stock, the SWS DCF model goes further and suggests CStone is trading above an estimated fair value of HK$0.95 per share at the current HK$8.02 price. If both methods flag rich pricing, where could a margin of safety come from?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 219 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment running high, it makes sense to move quickly and review the underlying data yourself before forming a stance. To weigh the upside potential against the concerns being raised, start by reviewing the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If CStone has your attention, do not stop here. The next strong idea could already fit your checklist, but only if you look for it now.

• Target companies with resilient financial footing by checking the solid balance sheet and fundamentals stocks screener (391 results) and see which stocks currently line up with your risk tolerance.
• Spot potential value opportunities early by reviewing the screener containing 531 high quality undiscovered gems before they move further onto the market’s radar.
• Prioritise capital protection by using the 307 resilient stocks with low risk scores to filter for stocks with lower overall risk scores that may suit a steadier approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com